Ipsen’s executive vice president of research and development and chief scientific officer Dr Claude Bertrand has stepped down from his post.
He will be replaced by Dr Alexandre Lebeaut as interim head of research and development while the firm searches for a permanent successor.
Dr Bertrand joined the French pharmaceutical firm in 2009, having moved from AstraZeneca where he most recently served as global vice president for launched and established brands.
Prior to this, Dr Bertrand held director-level and senior research positions at Novartis, Pfizer and Roche.
David Meek, chief executive officer of Ipsen, said: “On behalf of the company, I would like to thank Dr Bertrand for his significant contribution to leading the R&D organization during the past seven years.
“We wish him well as he moves on to pursue a new opportunity.”
He added: “We are fortunate to have an experienced and successful R&D leader like Dr Lebeaut to step up and lead the R&D team.”